Genoplexus Inc. Options Rights to Cancer Therapy

June 01, 2022

A startup company founded by Dr. Haluk Germeyan and Prakash Melvani, Genoplexus Inc., took an option to exclusively license commercial rights from GW. Genoplexus will evaluate commercialization of cancer therapy innovations jointly developed by Dr. Eric Yvon, Associate Professor of Medicine and Dr. Catherine Bollard, Associate Center Director for Translational Research at GW Cancer Center, and collaborators at Children’s National and Saarland University. The technology provides a new CAR-based cell therapy to selectively target cancer for elimination by immune cells.